Rigel Pharmaceuticals Profit Margin

The latest profit margin for RIGL is 1.22% as of March 2026. That compares with 18.31% in the prior-year period — up 563.7% year over year. That is above the Healthcare sector average of 15.58%. Investors often review this figure alongside Rigel Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, RIGL's profit margin moved from 18.31% to 1.22% — a 563.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Rigel Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, RIGL currently prints 1.22% for profit margin, while the sector average sits near 15.58%. That is roughly 679.7% above the sector mean. Large gaps often invite a closer look at Rigel Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Rigel Pharmaceuticals converts resources into returns. At 1.22%, RIGL may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 18.31% in the prior-year period — up 563.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RIGL's profit margin (1.22%), review year-over-year change from 18.31%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.